GAM Holding AG Sells 4,319 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

GAM Holding AG cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,327 shares of the medical research company's stock after selling 4,319 shares during the quarter. GAM Holding AG's holdings in Thermo Fisher Scientific were worth $5,482,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Halpern Financial Inc. boosted its position in Thermo Fisher Scientific by 307.7% during the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company's stock worth $27,000 after purchasing an additional 40 shares during the period. Coppell Advisory Solutions LLC bought a new position in Thermo Fisher Scientific during the second quarter worth $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific during the fourth quarter worth $36,000. Tyler Stone Wealth Management bought a new position in Thermo Fisher Scientific during the second quarter worth $37,000. Finally, Indiana Trust & Investment Management CO bought a new position in Thermo Fisher Scientific during the third quarter worth $38,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a "neutral" rating and a $620.00 price objective for the company. Sanford C. Bernstein reissued a "market perform" rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, December 13th. They issued an "outperform" rating and a $575.00 target price for the company. Barclays cut shares of Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and boosted their target price for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, HSBC initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a "buy" rating and a $610.00 target price for the company. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $599.00.

Thermo Fisher Scientific Price Performance

TMO stock traded up $4.83 during midday trading on Wednesday, reaching $576.39. The company had a trading volume of 1,151,542 shares, compared to its average volume of 1,595,402. The company has a market capitalization of $219.78 billion, a price-to-earnings ratio of 36.99, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80. The stock has a 50 day moving average price of $567.37 and a 200-day moving average price of $522.08. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business's quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.40 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific's payout ratio is presently 10.10%.

Insiders Place Their Bets

In related news, Director Debora L. Spar sold 164 shares of the firm's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Marc N. Casper sold 5,547 shares of the firm's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the completion of the transaction, the chief executive officer now owns 43,608 shares in the company, valued at approximately $24,011,436.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of the firm's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company's stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.